Oasmia Pharmaceutical AB Announces Pricing of Public Offering of American Depositary Shares and NASDAQ Listing

NEW YORK, NY –October 23, 2015 – Oasmia Pharmaceutical AB (NASDAQ: OASM), is a specialty pharmaceutical company focused on innovative treatments within human and animal oncology ("Oasmia" or the "Company"). Oasmia's product and product candidates utilize a proprietary, nanoparticle formulation technology that is designed to facilitate the administration of intravenously-delivered active pharmaceutical ingredients, without the addition of toxic solvents. Oasmia today announced the pricing of a U.S. underwritten public offering of American Depositary Shares, or ADSs, and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price of $4.06 per ADS and $0.0025 per warrant. Each ADS represents three of Oasmia's ordinary shares. The Company expects to receive gross proceeds of approximately $9,500,076 million from this offering, before deducting underwriting discounts, commissions and other related expenses. The warrants have an exercise price of $4.06, are exercisable immediately and will expire ten years from the date of issuance. The ADSs and Warrants will be separately issued, but will be issued together and sold in the proportions described above. The offering is expected to close on October 28, 2015, subject to customary closing conditions. The Company has also granted the underwriters a 45-day option to purchase up to (i) 350,880 additional ADSs and (ii) additional warrants to purchase up to 175,440 ADSs to cover over-allotments, if any. 

Oasmia also announced that its ADSs will begin trading on The NASDAQ Capital Market under the symbol "OASM" on October 23, 2015. 

Proceeds from this offering will be used to fund: (i) new clinical trials and other regulatory requirements of Oasmia's product and product candidates, (ii) production development, including validation batches, and (iii) other general corporate purposes, including employees, rent, and costs and expenses of being a U.S. public company.  

Rodman & Renshaw, a unit of H.C. Wainwright & Co. and Joseph Gunnar & Co., LLC are acting as joint book-running managers in this offering. 

A registration statement on Form F-1 relating to this offering has been filed with the Securities and Exchange Commission ("SEC") and has been declared effective by the SEC as of October 22, 2015. The offering of these securities will be made only by means of a prospectus, forming a part of the registration statement. A preliminary prospectus relating to the offering is included in the F-1 filed with the SEC and is available on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from Oasmia, with an address of Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: [email protected] In addition, the registration statement, including the prospectus, is available to the public at www.sec.gov or www.oasmia.com.  In addition, you may contact Rodman & Renshaw, a unit of H.C. Wainwright & Co., 430 Park Avenue, 4th Floor, New York, NY 10022, email: [email protected] and Joseph Gunnar & Co, LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: [email protected] 

Sichenzia Ross Friedman Ference LLP is acting as U.S. legal counsel to Oasmia, and McGuireWoods LLP is acting as legal counsel to the underwriters. 

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction. 

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365). 

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…